Perspective Therapeutics is pioneering targeted alpha therapies using Lead-212, focusing on precision oncology through a theranostic approach. Its clinical programs for neuroendocrine tumors, melanoma, and solid tumors progress with growing patient cohorts and dose escalations. Financially, the company continues navigating significant operating losses typical of early-stage biotech while bolstering its cash position via a $175 million equity offering to extend runway into late 2027. Manufacturing investments and intellectual property strengthen operational scalability, though regulatory and market challenges remain key risks.